

Maja Krajinovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9466214/publications.pdf>

Version: 2024-02-01

113
papers

4,185
citations

126858

33
h-index

118793

62
g-index

116
all docs

116
docs citations

116
times ranked

4220
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. <i>Blood</i> , 2008, 112, 2024-2027.	0.6	222
2	Susceptibility to Childhood Acute Lymphoblastic Leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 Genetic Polymorphisms. <i>Blood</i> , 1999, 93, 1496-1501.	0.6	211
3	Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 3832-3834.	0.6	201
4	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , 2016, 3, e526-e536.	2.2	197
5	Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2004, 103, 252-257.	0.6	193
6	Risk of Childhood Leukemia Associated with Exposure to Pesticides and with Gene Polymorphisms. <i>Epidemiology</i> , 1999, 10, 481-487.	1.2	187
7	Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. <i>Lancet</i> , 2002, 359, 1033-1034.	6.3	158
8	Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2004, 4, 66-72.	0.9	152
9	Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 2002, 97, 230-236.	2.3	137
10	Genetic susceptibility to breast cancer in French-Canadians: Role of carcinogen-metabolizing enzymes and gene-environment interactions. <i>International Journal of Cancer</i> , 2001, 92, 220-225.	2.3	111
11	Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2002, 8, 802-10.	3.2	106
12	DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. <i>Blood</i> , 2008, 111, 3692-3700.	0.6	104
13	Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 38, 447-462.	0.6	97
14	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 1383-1386.	0.6	83
15	Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2016, 16, 530-535.	0.9	81
16	Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2014, 15, 1105-1116.	0.6	75
17	Pharmacogenetics of methotrexate. <i>Pharmacogenomics</i> , 2004, 5, 819-834.	0.6	74
18	Rapid Detection of CYP1A1, CYP2D6, and NAT Variants by Multiplex Polymerase Chain Reaction and Allele-Specific Oligonucleotide Assay. <i>Analytical Biochemistry</i> , 1999, 275, 84-92.	1.1	68

#	ARTICLE	IF	CITATIONS
19	Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. <i>European Respiratory Journal</i> , 2017, 50, 1700148.	3.1	67
20	The PETALE study: Late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26361.	0.8	66
21	Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. <i>Haematologica</i> , 2006, 91, 1113-6.	1.7	66
22	Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 655-658.	5.7	65
23	Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. <i>Pharmacogenomics</i> , 2005, 6, 293-302.	0.6	58
24	Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. <i>Pharmacogenomics Journal</i> , 2005, 5, 374-380.	0.9	55
25	Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 329-334.	3.2	52
26	Characterization of the BclI Polymorphism in the Glucocorticoid Receptor Gene. <i>Clinical Chemistry</i> , 2003, 49, 1528-1531.	1.5	49
27	Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. <i>Journal of Lipid Research</i> , 2017, 58, 982-993.	2.0	49
28	ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 5883-5890.	0.6	46
29	Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. <i>Bone Marrow Transplantation</i> , 2013, 48, 939-946.	1.3	43
30	The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 577-580.	5.7	41
31	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017, 8, 90852-90867.	0.8	39
32	Trypsin-encoding <i>PRSS1-PRSS2</i> variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. <i>Haematologica</i> , 2019, 104, 556-563.	1.7	36
33	Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. <i>Current Opinion in Pediatrics</i> , 2007, 19, 15-22.	1.0	35
34	Polymorphisms in Genes Involved in the Corticosteroid Response and the Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Molecular Diagnosis and Therapy</i> , 2004, 4, 331-341.	3.3	34
35	DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2009, 15, 6931-6938.	3.2	34
36	Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Children. <i>Current Drug Metabolism</i> , 2014, 15, 251-264.	0.7	34

#	ARTICLE	IF	CITATIONS
37	Characterization of the microDNA through the response to chemotherapeutics in lymphoblastoid cell lines. <i>PLoS ONE</i> , 2017, 12, e0184365.	1.1	33
38	Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. <i>Oncotarget</i> , 2017, 8, 43752-43767.	0.8	33
39	Childhood Acute Lymphoblastic Leukemia: Genetic Determinants of Susceptibility and Disease Outcome. <i>Reviews on Environmental Health</i> , 2001, 16, 263-79.	1.1	30
40	The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. <i>Pharmacogenomics Journal</i> , 2014, 14, 263-271.	0.9	29
41	Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL). <i>Leukemia Research</i> , 2010, 34, 492-497.	0.4	27
42	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 115-119.	0.9	27
43	Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1502.	1.8	27
44	The pharmacogenetics of imanitib. <i>Genome Medicine</i> , 2010, 2, 85.	3.6	26
45	Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2012, 12, 386-394.	0.9	26
46	Incorporation of <i>GSTA1</i> genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1494-1504.	1.1	25
47	Pharmacogenomics of acute leukemia. <i>Pharmacogenomics</i> , 2007, 8, 817-834.	0.6	24
48	Novel therapy for childhood acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1081-1099.	0.9	24
49	<i>Bim</i> Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5240-5249.	3.2	21
50	Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. <i>Leukemia Research</i> , 2007, 31, 1023-1025.	0.4	18
51	Can the pharmacogenetics of <i>GST</i> gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?. <i>Pharmacogenomics</i> , 2009, 10, 1729-1732.	0.6	17
52	Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: A PETALE study. <i>Clinical Nutrition</i> , 2019, 38, 912-919.	2.3	17
53	A 2-year dyadic longitudinal study of mothers' and fathers' marital adjustment when caring for a child with cancer. <i>Psycho-Oncology</i> , 2017, 26, 1660-1666.	1.0	16
54	GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1918-1924.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 143-156.	0.4	16
56	Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2019, 19, 33-41.	0.9	16
57	Physical Activity and Sedentary Behaviors in Childhood Acute Lymphoblastic Leukemia Survivors. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 53-60.	0.3	16
58	Genomic loci susceptible to replication errors in cancer cells. <i>British Journal of Cancer</i> , 1998, 78, 981-985.	2.9	15
59	Self-priming arrest by modified random oligonucleotides facilitates the quality control of whole genome amplification. <i>Analytical Biochemistry</i> , 2005, 339, 345-347.	1.1	15
60	Spontaneous brain oscillations as neural fingerprints of working memory capacities: A resting-state MEG study. <i>Cortex</i> , 2017, 97, 109-124.	1.1	15
61	Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 699-719.	1.5	14
62	Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors. <i>BMC Cancer</i> , 2017, 17, 751.	1.1	14
63	DIVERGT screening procedure predicts general cognitive functioning in adult long-term survivors of pediatric acute lymphoblastic leukemia: A PETALE study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27259.	0.8	14
64	Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study. <i>PLoS ONE</i> , 2019, 14, e0217314.	1.1	14
65	The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 687-693.	1.1	14
66	Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy. <i>Developmental Disabilities Research Reviews</i> , 2008, 14, 211-220.	2.9	13
67	<i>MTHFD1</i> gene: role in disease susceptibility and pharmacogenetics. <i>Pharmacogenomics</i> , 2008, 9, 829-832.	0.6	13
68	Development and relative validation of a food frequency questionnaire for French-Canadian adolescent and young adult survivors of acute lymphoblastic leukemia. <i>Nutrition Journal</i> , 2018, 17, 45.	1.5	13
69	Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. <i>Pharmacogenomics Journal</i> , 2018, 18, 64-69.	0.9	13
70	How to interpret high levels of distress when using the Distress Thermometer in the long-term follow-up clinic? A study with Acute Lymphoblastic Leukemia survivors. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 131-135.	0.3	11
71	Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity. <i>Pharmacogenomics Journal</i> , 2018, 18, 270-274.	0.9	11
72	DNA variants in <i>DHFR</i> gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. <i>Pharmacogenomics</i> , 2018, 19, 105-112.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Altered proteome of high-density lipoproteins from paediatric acute lymphoblastic leukemia survivors. <i>Scientific Reports</i> , 2019, 9, 4268.	1.6	11
74	Dietary Intakes Are Associated with HDL-Cholesterol in Survivors of Childhood Acute Lymphoblastic Leukaemia. <i>Nutrients</i> , 2019, 11, 2977.	1.7	11
75	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 920-927.	2.0	11
76	Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 314-321.	1.7	10
77	Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 865-883.	1.5	10
78	Role of NOS3 DNA Variants in Externalizing Behavioral Problems Observed in Childhood Leukemia Survivors. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e157-e162.	0.3	9
79	Current perspective on pediatric pharmacogenomics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 363-365.	1.5	9
80	Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. <i>BMC Cancer</i> , 2019, 19, 443.	1.1	9
81	HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCl Consortium. <i>Pharmacogenomics</i> , 2020, 21, 541-547.	0.6	9
82	Identification of a single-nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors. <i>Pharmacogenomics</i> , 2019, 20, 409-420.	0.6	8
83	Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1819-1827.	2.0	8
84	Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients. <i>Mediators of Inflammation</i> , 2011, 2011, 1-6.	1.4	7
85	Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , 2019, 20, 1189-1197.	0.6	7
86	<i>RGS5</i> gene and therapeutic response to short acting bronchodilators in paediatric asthma patients. <i>Pediatric Pulmonology</i> , 2013, 48, 970-975.	1.0	6
87	Predictors of Vertebral Deformity in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia: The PETALE Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 512-525.	1.8	6
88	Genetic Predictors for Sinusoidal Obstruction Syndrome—A Systematic Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 347.	1.1	5
89	Pharmacogenetics of asparaginase in acute lymphoblastic leukemia. <i>Cancer Drug Resistance (Alhambra)</i> , 2021, 4, 109-115.	0.9	5
90	Contributing Factors of Unmet Needs Among Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia with Comorbidities. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 462-475.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Heart rate response and chronotropic incompetence during cardiopulmonary exercise testing in childhood acute lymphoblastic leukemia survivors. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 564-580.	0.3	4
92	Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study. <i>Leukemia Research</i> , 2019, 86, 106228.	0.4	3
93	Magnetoencephalography resting-state correlates of executive and language components of verbal fluency. <i>Scientific Reports</i> , 2022, 12, 476.	1.6	3
94	<p>Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 33-45.	0.4	2
95	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2697-2704.	1.3	2
96	Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors. <i>Pharmacogenomics Journal</i> , 2022, 22, 19-24.	0.9	2
97	Visual short term memory related brain activity predicts mathematical abilities.. <i>Neuropsychology</i> , 2017, 31, 535-545.	1.0	2
98	Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2003, 1, 87-100.	0.3	2
99	Influence Of GST Gene Polymorphisms On Busulfan Pharmacokinetics and Outcome Of Hematopoietic Stem Cell Transplantation In Thalassemia Pediatric Patients. <i>Blood</i> , 2013, 122, 2052-2052.	0.6	2
100	Is there a relationship between vitamin D nutritional status and metabolic syndrome in childhood acute lymphoblastic leukemia survivors? A PETALE study. <i>Clinical Nutrition ESPEN</i> , 2019, 31, 28-32.	0.5	1
101	Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2021, 22, 885-901.	0.6	1
102	Lactic Acidosis with Chloramphenicol Treatment in a Child with Cystic Fibrosis. , 2017, 24, 40-45.		1
103	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. <i>Pharmacogenomics Journal</i> , 2022, 22, 9-18.	0.9	1
104	A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 5.	1.0	1
105	Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. <i>Personalized Medicine</i> , 2008, 5, 325-329.	0.8	0
106	Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols. <i>Leukemia Research</i> , 2021, 109, 106650.	0.4	0
107	Polymorphisms in Multidrug Resistance-Associated Protein Genes Are Associated with Worse Outcome in Childhood Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 1443-1443.	0.6	0
108	Special Challenges: Genetic Polymorphisms and Therapy. , 2011, , 315-330.		0

#	ARTICLE	IF	CITATIONS
109	Myeloablative Conditioning with Pharmacokinetic-Targeted Intravenous Busulfan and Cyclophosphamide in Unrelated Cord Blood Transplantation for Myeloid Malignancies in Children. <i>Blood</i> , 2011, 118, 1965-1965.	0.6	0
110	Sulfolane (a metabolite of busulfan) Levels Could Predict Occurrence Of Hemorrhagic Cystitis In Children Receiving Busulfan Based Myeloablative Conditioning Before Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 4574-4574.	0.6	0
111	GSTA1 Genotype Influences Performance of Initial Bu Prediction Methods during Conditioning before SCT. <i>Blood</i> , 2015, 126, 4323-4323.	0.6	0
112	DÉVELOPPEMENT NEUROCOGNITIF ET CÉRÉBRAL DES SURVIVANTS À LONG TERME DE LA LEUCÉMIE LYMPHOBLASTIQUE AIGUË. <i>Revue Québécoise De Psychologie</i> , 2016, 37, 43-63.	0.0	0
113	Characterization of the impact of <i>MYBBP1A</i> gene and rs3809849 on asparaginase sensitivity and cellular functions. <i>Pharmacogenomics</i> , 2022, 23, 415-430.	0.6	0